OTLK is way oversold on news. Under .25 and target at $1, "Cantor Fitzgerald analyst Kristen Kluska downgrades Outlook Therapeutics (NASDAQ:OTLK) from Overweight to Neutral and lowers the price target from $4.5 to $1."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.